X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (10) 10
adult (9) 9
middle aged (9) 9
female (8) 8
male (8) 8
performing operations (7) 7
transporting (7) 7
apparatus for making beverages (6) 6
coffee mills (6) 6
domestic articles or appliances (6) 6
for performing mechanical work in general (6) 6
furniture (6) 6
generating or transmitting mechanical vibrations in general (6) 6
hiv infections - drug therapy (6) 6
human necessities (6) 6
infectious diseases (6) 6
kitchen equipment (6) 6
methods or apparatus for generating or transmitting mechanicalvibrations of infrasonic, sonic, or ultrasonic frequency (6) 6
spice mills (6) 6
suction cleaners in general (6) 6
anti-hiv agents - therapeutic use (5) 5
hiv (5) 5
immunology (5) 5
aged (4) 4
analogous arrangements using other waves (4) 4
determining distance or velocity by use of radio waves (4) 4
drug resistance, viral (4) 4
drug therapy, combination (4) 4
hiv infections - virology (4) 4
hiv-1 - drug effects (4) 4
human-immunodeficiency-virus (4) 4
locating or presence-detecting by use of the reflection orreradiation of radio waves (4) 4
measuring (4) 4
pharmacology & pharmacy (4) 4
physics (4) 4
radio direction-finding (4) 4
radio navigation (4) 4
testing (4) 4
adolescent (3) 3
aids/hiv (3) 3
article (3) 3
coffee (3) 3
double-blind (3) 3
foods or foodstuffs (3) 3
genotype (3) 3
hiv-1-infected patients (3) 3
manufacture, preparation, or infusion thereof (3) 3
research (3) 3
rna, viral - blood (3) 3
tea (3) 3
their substitutes (3) 3
their treatment, not covered by other classes (3) 3
viral load (3) 3
abridged index medicus (2) 2
activation energy (2) 2
aids (2) 2
analysis (2) 2
anti-hiv agents - pharmacology (2) 2
antiretroviral drugs (2) 2
antiretroviral therapy (2) 2
antiviral agents - adverse effects (2) 2
anxiety (2) 2
articles (2) 2
biomass energy production (2) 2
care and treatment (2) 2
cd4 lymphocyte count (2) 2
cirrhosis (2) 2
cohort studies (2) 2
combination therapy (2) 2
death (2) 2
devolatilization (2) 2
dosage and administration (2) 2
double-blind method (2) 2
drug therapy (2) 2
efficacy (2) 2
emtricitabine (2) 2
evolution (2) 2
genotypes (2) 2
hepacivirus - drug effects (2) 2
hepacivirus - genetics (2) 2
hepatitis (2) 2
hepatitis c (2) 2
hepatitis c virus (2) 2
hepatitis c, chronic - drug therapy (2) 2
hiv infections - complications (2) 2
hiv protease - genetics (2) 2
hiv protease inhibitors - pharmacology (2) 2
hiv reverse transcriptase - genetics (2) 2
hiv-1 (2) 2
hiv-1 - genetics (2) 2
hiv-1 - isolation & purification (2) 2
human immunodeficiency virus--hiv (2) 2
interferon (2) 2
liver (2) 2
mathematical models (2) 2
microbiology (2) 2
mortality (2) 2
mutation (2) 2
patients (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 08/2014, Volume 210, Issue 3, pp. 354 - 362
Journal Article
The lancet. HIV, ISSN 2352-3018, 01/2020, Volume 7, Issue 1, pp. e16 - e26
Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior... 
Journal Article
Journal Article
01/2015, ISBN 9781321814798
There have been many recent instances of teachers being disciplined or terminated due to their activity on social networking sites. School administrators will... 
Law | School administration | Educational leadership
Dissertation
by Zeuzem, S and Flisiak, R and Vierling, J. M and Mazur, W and Mazzella, G and Thongsawat, S and Abdurakhmanov, D and Van Kính, N and Calistru, P and Heo, J and Stanciu, C and Gould, M and Makara, M and Hsu, S.‐J and Buggisch, P and Samuel, D and Mutimer, D and Nault, B and Merz, M and Bao, W and Griffel, L. H and Brass, C and Naoumov, N. V and Tanno, Hugo and Bessone, Fernando and Terg, Ruben and Frider, Bernardo and Bertuzzi, Romina and Desmond, Paul and Zekry, Amany and Weltman, Martin and George, Jacob and Crawford, Darrell and Matthews, Gail and Moreno, Christophe and Vlierberghe, Hans and Reynaert, Hendrik and Gould, Michael and Lee, Samuel and Ramji, Alnoor and Tam, Edward and Marotta, Paul and Yoshida, Eric and Wong, Florence and Feld, Jordan and Samuel, Didier and Marcellin, Patrick and Alric, Laurent and Zarski, Jean‐Pierre and Zoulim, Fabien and Buggisch, Peter and Hinrichsen, Holger and Goeser, Tobias and Zeuzem, Stefan and Galle, Peter and Berg, Thomas and Schott, Eckart and Rasenack, Jens and Gerken, Guido and Wedemeyer, Hans and Tsang, Owen and Yuen, Man‐Fung and Chan, Henry and Hui, Aric Josun and Makara, Mihaly and Tornai, Istvan and Gervain, Judit and Szalay, Ferenc and Varga, Marta and Horvath, Gabor and Hunyady, Bela and Vincze, Aron and Mazzella, Giuseppe and Gaeta, Giovanni Battista and Alberti, Alfredo and Colombo, Massimo and Andreone, Pietro and Rizzetto, Mario and Angelico, Mario and Craxi, Antonio and Picciotto, Antonino and Sacchi, Paolo and Vinci, Maria and Invernizzi, Pietro and Bruno, Savino and Heo, Jeong and Lee, Younjae and Cho, Mong and Han, Sangyoung and Lee, Jinwoo and Ahn, Sanghoon and Lim, Youngsuk and Hwang, Seonggyu and Sanchez, Juan and Muñoz, Linda and Maldonado, Hector and Mazur, Wlodzimierz and Flisiak, Robert and Jablkowski, Maciej and Kryczka, Wieslaw and ... and ESSENTIAL II Study Grp and ESSENTIAL II Study Group and the ESSENTIAL II Study Group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 10/2015, Volume 42, Issue 7, pp. 829 - 844
Summary Background Alisporivir (ALV) is an oral, host‐targeting agent with pangenotypic anti‐hepatitis C virus (HCV) activity and a high barrier to resistance.... 
PLUS RIBAVIRIN | CYCLOPHILIN INHIBITOR | VIRUS-INFECTION | ANTIVIRAL TREATMENT | CHRONIC HEPATITIS-C | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INTERFERON-ALPHA 2A | LIVER-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | INDUCED PANCREATITIS | DEBIO 025 | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Young Adult | Ribavirin - administration & dosage | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Double-Blind Method | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cyclosporine - adverse effects | Adolescent | Cyclosporine - administration & dosage | Aged | Interferon-alpha - adverse effects | Hypertension | Thrombocytopenia | Therapy | Anemia | Pancreatitis | Chronic infection | Clinical trials | Viruses | Infections | Patients | Ribavirin | Cirrhosis | Disease resistance | Hepatitis | Genotype & phenotype | Randomization | Interferon | Hepatitis C virus | Hepatitis C | Genotypes
Journal Article
by Cahn, PE and Cahn, Pedro and Kaplan, Richard and Kaplan, R and Sax, Paul E and Squires, Kathleen and Molina, Jean-Michel and Avihingsanon, Anchalee and Avihingsanon, A and Ratanasuwan, W and Ratanasuwan, Winai and Rojas, Evelyn and Rojas, EM and Rassool, Mohammed and Rassool, MS and Bloch, MT and Bloch, Mark and Vandekerckhove, Linos and Ruane, Peter and Ruane, PJ and Yazdanpanah, Yazdan and Yazdanpanah, Y and Katlama, C and Katlama, Christine and Xu, Xia and Rodgers, Anthony and East, Lilly and Wenning, Larissa and Rawlins, Sandy and Homony, Brenda and Sklar, Peter and Nguyen, Bach-Yen and Leavitt, Randi and Teppler, Hedy and Cassetti, I and Losso, M and Roth, N and McMahon, J and Moore, RJ and Smith, D and Smith, GHR and Clumeck, N and Vanderkerckhove, L and Vandercam, B and Moutschen, M and Baril, J and Conway, B and Smaill, F and Rachlis, A and Walmsley, SL and Perez, C and Wolff, M and Lasso, MF and Chahin, CE and Velez, JD and Sussmann, O and Reynes, J and Ferret, S and Durant, J and Duvivier, C and Poizot-Martin, I and Ajana, F and Rockstroh, JK and Faetkanheuer, G and Esser, S and Jaeger, H and Degen, O and Bickel, M and Bogner, J and Arasteh, K and Hartl, H and Stoehr, A and Arathoon, E and Gonzalez, LD and Mejia, CR and Shahar, E and Turner, D and Levy, I and Sthoeger, Z and Elinav, H and Gori, A and Monforte, A D'Arminio and Di Perri, G and Lazzarin, A and Rizzardini, G and Antinori, A and Celesia, BM and Maggiolo, F and Chow, TS and Lee, CKC and Azwa, R Iskandar Shah Raja and Mustafa, M and Oyanguren, M and Castillo, RA and Hercilla, L and Echiverri, C and Maltez, F and da Cunha, JG Saraiva and Neves, I and Teofilo, E and ... and ONCEMRK Study Grp and ONCEMRK Study Group
The Lancet HIV, ISSN 2352-3018, 11/2017, Volume 4, Issue 11, pp. e486 - e494
Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of... 
INFECTIOUS DISEASES | TREATMENT ADHERENCE | EFFICACY | PHARMACOKINETICS | COMBINATION THERAPY | EFAVIRENZ | CO-FORMULATED ELVITEGRAVIR | DAILY DOLUTEGRAVIR | INITIAL TREATMENT | QUALITY-OF-LIFE | IMMUNOLOGY | ANTIRETROVIRAL-NAIVE ADULTS | Life Sciences | Human health and pathology | Immunology | Infectious diseases
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 4/2009, Volume 48, Issue 8, pp. 1138 - 1151
Journal Article